NCT00006436 2025-12-30
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
8 trialsNCT02911142 2025-07-28
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT03220022 2025-07-18
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT00001563 2022-01-19
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01045889 2016-08-19
HDT-HIV
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT00310128 2016-02-03
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
AIDS Malignancy Consortium
Phase 2 Withdrawn
NCT00799136 2013-09-12
CATCH
Ontario Clinical Oncology Group (OCOG)
Phase 2 Completed
NCT00126243 2005-08-17
Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma
French National Agency for Research on AIDS and Viral Hepatitis
Phase 2 Terminated